Print Page | Close Window

Cytokinetics, Inc. (NASDAQ: CYTK) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and other medical conditions.  Cytokinetics currently has three compounds in clinical development: omecamtiv mecarbil in Phase II for acute and chronic heart failure... Details >>

Link to Annual Report & Stockholder Meeting Materials and Information

Stock Quote
CYTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.17 (2.61%)
Market Cap$245,852,950
Shares Outstanding38,717,000
Data as of 07/02/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsDetails >>
06/19/15Cytokinetics Presents Results From Phase I Studies of CK-2127107Printer Friendly Version
06/16/15Cytokinetics to Present at the 9th Annual JMP Securities Life Sciences Conference 2015Printer Friendly Version
06/11/15Cytokinetics Announces Poster Presentation on CK-2127107 at the 19th International SMA Researcher MeetingPrinter Friendly Version
06/04/15Cytokinetics and The ALS Association Announce Partnership to Advance the Fight Against ALSPrinter Friendly Version
Upcoming EventsDetails >>
There are currently no events scheduled.
Featured ReportDetails >>
Download Documentation 2014 Annual Report

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.